<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00651040</url>
  </required_header>
  <id_info>
    <org_study_id>3401</org_study_id>
    <nct_id>NCT00651040</nct_id>
  </id_info>
  <brief_title>Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM</brief_title>
  <acronym>Prometheus</acronym>
  <official_title>A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Rheumatology, Prague</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Rheumatology, Prague</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutical trial in patients with idiopathic polymyositis (PM) and dermatomyositis (DM) is&#xD;
      proposed. The study will investigate the safety and efficacy of combined methotrexate (MTX) +&#xD;
      glucocorticoids (GC) treatment compared with GC alone.&#xD;
&#xD;
      This will be a randomised, open-label, assessor-blind, international multicenter trial,&#xD;
      performed in several European centres interested in research on inflammatory myopathies&#xD;
      (IIM).&#xD;
&#xD;
      A total number of 50 patients with PM/DM will be randomised into two groups (1: MTX+ GC and&#xD;
      2: GC only). Patients will be equally distributed between the two groups providing 25&#xD;
      patients per treatment arm. The randomisation will be based on random numbers generated by a&#xD;
      computer program. After being enrolled in the study, the patients will receive 12 months of&#xD;
      therapy followed by a 12-month follow-up period.&#xD;
&#xD;
      The primary endpoint is the total dose of GC ( in mg/kg weight), which will be administered&#xD;
      for 12 months between baseline and the end of treatment.&#xD;
&#xD;
      There are several of secondary objectives, which will be pursued during and after the trial.&#xD;
      Disease activity and damage will be prospectively assessed by tools for myositis disease&#xD;
      activity (MYOACT and MITAX) and for myositis damage (MYODAM and MDI), global assessment of&#xD;
      activity and damage by patients and by physician, muscle endurance, muscle strength by manual&#xD;
      muscle testing, enzyme levels, GC related side effects, functional ability measured by HAQ,&#xD;
      quality of life by SF-36, and number of patients with treatment failures. The other aims will&#xD;
      also include (i) search for reliable prognostic parameters in the further prognosis of&#xD;
      patients with PM/DM and (ii) studies on the pathogenic aspects of IIM. The investigations of&#xD;
      serum, lymphocytes, muscle tissue and MRI will be organized. DNA and RNA will be stored for&#xD;
      future genetic studies.&#xD;
&#xD;
      Patients with definite or probable PM or DM diagnosed according to diagnostic criteria will&#xD;
      be enrolled. They will have disease activity that according to physician's own judgement&#xD;
      requires high dose immunosuppressive treatment (based on clinical assessment of weakness,&#xD;
      elevation of muscle enzymes and, if available, on magnetic resonance imaging findings).&#xD;
      Patients should be previously untreated with the exception of GC treatment up to 8 weeks.&#xD;
&#xD;
      Patients with other than primary idiopathic PM or DM, such as drug-induced myositis, myositis&#xD;
      in association with other connective tissue disease, inclusion body myositis, malignancy&#xD;
      related myositis, and juvenile DM will be excluded.&#xD;
&#xD;
      All patients will start with prednisone 1 mg/kg/day and the dose will be tapered if patients&#xD;
      meet definition of improvement, which has been proposed by IMACS group. MTX will be&#xD;
      administered orally, once weekly, with a starting dose 10 mg. This will be increased&#xD;
      gradually to 25 mg/week if tolerated by week 5. Patients will be first assessed after 2 weeks&#xD;
      and than monthly for a period of 48 weeks. There will be a follow-up after a further 1 year&#xD;
      in order to find out the impact of the early treatment on the long-term disease outcome.&#xD;
&#xD;
      All efficacy analyses will be performed using intention-to-treat population (ITT). In&#xD;
      addition, the primary and secondary variables will be analysed using the per-protocol&#xD;
      population, which will contain all patients in the ITT population, who also reached Week 48&#xD;
      without any major protocol violations. The safety population, which will contain any patient&#xD;
      who received at least one dose of study drug, will be used for all safety analyses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial:&#xD;
&#xD;
      A prospective, randomized, assessor- blind, multicenter study of safety and efficacy of&#xD;
      combined treatment of methotrexate and glucocorticoids versus glucocorticoids alone in&#xD;
      patients with polymyositis and dermatomyositis&#xD;
&#xD;
      Tested investigational medicinal product: Methotrexate (Methotrexatum dinatricum 2,5 mg&#xD;
      tbl.).&#xD;
&#xD;
      Mechanism of Action: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must&#xD;
      be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of&#xD;
      one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore,&#xD;
      methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively&#xD;
      proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and&#xD;
      intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this&#xD;
      effect of methotrexate.&#xD;
&#xD;
      Comparator : Prednison (Prednisonum 20 mg tbl.)&#xD;
&#xD;
      Mechanism of Action: Glucocorticoids are naturally occurring hormones that prevent or&#xD;
      suppress inflammation and immune responses when administered at pharmacological doses. At a&#xD;
      molecular level, unbound glucocorticoids readily cross cell membranes and bind with high&#xD;
      affinity to specific cytoplasmic receptors. This binding induces a response by modifying&#xD;
      transcription and, ultimately protein synthesis to achieve the steroid's intended action.&#xD;
      Such actions may include: inhibition of leukocyte infiltration at the site of inflammation,&#xD;
      interference in the function of mediators of inflammatory response, and suppression of&#xD;
      humoral immune responses. Some of the net effects include reduction in edema or scar tissue,&#xD;
      as well as a general suppression in immune response. The degree of clinical effect is&#xD;
      normally related to the dose administered. The antiinflammatory actions of corticosteroids&#xD;
      are thought to involve phospholipase A2 inhibitory proteins, collectively called lipocortins.&#xD;
      Lipocortins, in turn, control the biosynthesis of potent mediators of inflammation such as&#xD;
      prostaglandins and leukotrienes by inhibiting the release of the precursor molecule&#xD;
      arachidonic acid. Likewise, the numerous adverse effects related to corticosteroid use are&#xD;
      usually related to the dose administered and the duration of therapy.&#xD;
&#xD;
      Number of patients in the trial:&#xD;
&#xD;
        -  Total 50&#xD;
&#xD;
        -  In this centre: 10&#xD;
&#xD;
      Summary:&#xD;
&#xD;
      The aim of the study is to determine the safety and efficacy of adding methotrexate (MTX) to&#xD;
      glucocorticoids (GC) compared with glucocorticoid treatment alone in patients with&#xD;
      inflammatory myopathies.&#xD;
&#xD;
        1. PM and DM are usually treated with glucocorticoids and immunosuppressive drugs. However,&#xD;
           such treatment has not yet been studied thoroughly and properly evaluated in a&#xD;
           randomized controlled trial. There are only few controlled studies of PM/DM management&#xD;
           and all of them have been performed in small groups of patients. This will be the first&#xD;
           randomized controlled trial with MTX&#xD;
&#xD;
        2. This clinical trial will assess efficacy MTX in patients with early PM/DM&#xD;
&#xD;
        3. Also long- term effect of treatment (MTX and glucocorticoids versus glucocorticoids)&#xD;
           will be evaluated.&#xD;
&#xD;
        4. Inclusion criteria allow to follow up the consistent group of PM/DM patients.&#xD;
&#xD;
        5. In this trial the of newly developed tools for myositis disease activity will be used&#xD;
&#xD;
        6. The secondary objectives is to study pathogenic aspects of inflammatory myopathies.&#xD;
&#xD;
        7. The serum, DNA and RNA will be stored for future genetic studies and to study&#xD;
           autoantibodies to search for prognostic markers.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The primary objective of the study is to determine the safety and efficacy of adding&#xD;
      methotrexate (MTX) to glucocorticoids (GC) compared with glucocorticoid treatment alone in&#xD;
      patients with inflammatory myopathies. The primary endpoint that will be measured is the&#xD;
      total dose of glucocorticoids (in mg/kg weight) administered between baseline and the end of&#xD;
      treatment.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        1. Assessment of disease activity and damage [with the use of newly developed tools for&#xD;
           myositis disease activity (MYOACT and MITAX) and myositis damage (MYODAM and MDI), as&#xD;
           well as by global assessment of activity and damage by patients and by physician.&#xD;
&#xD;
        2. Muscle strength by manual muscle testing&#xD;
&#xD;
        3. Muscle endurance&#xD;
&#xD;
        4. Muscle enzyme levels&#xD;
&#xD;
        5. Glucocorticoid related side-effects&#xD;
&#xD;
        6. Final glucocorticoid dose&#xD;
&#xD;
        7. Disability index by HAQ&#xD;
&#xD;
        8. Quality of life by SF-36&#xD;
&#xD;
        9. Number of patients with treatment failures&#xD;
&#xD;
       10. Search for reliable prognostic parameters in the further prognosis of patients with&#xD;
           inflammatory myopathies.&#xD;
&#xD;
      Study of the pathogenic aspects of inflammatory myopathies. Therefore investigations of&#xD;
      serum, lymphocytes, muscle tissue and MRI will be organized. DNA and RNA will be stored for&#xD;
      future genetic studies.&#xD;
&#xD;
      Study design.&#xD;
&#xD;
      This will be a randomized, assessor-blinded, multicenter, international study. After being&#xD;
      enrolled in the study, the patients will receive 48 weeks of therapy followed by a 12-month&#xD;
      follow-up period.&#xD;
&#xD;
      A total number of 50 patients with polymyositis/dermatomyositis are planned to be randomized.&#xD;
      These will be equally distributed between the two groups providing 25 patients per treatment&#xD;
      arm. Patients will be randomized on the basis of random numbers generated by a computer&#xD;
      program.&#xD;
&#xD;
      Indication:&#xD;
&#xD;
      Treatment of active polymyositis and dermatomyositis&#xD;
&#xD;
      Evaluations.&#xD;
&#xD;
      Efficacy. The efficacy will be assessed by fulfillment of definition of improvement at every&#xD;
      visit and treatment taper with glucocorticoids. Overall efficacy will be assessed by&#xD;
      measurement of disease activity (MITAX, MYOACT), disease damage (MDI, MYODAM), global&#xD;
      patient's and physician's assessments, manual muscle strength test, functional muscle test2,&#xD;
      health assessment questionnaire (HAQ), and SF36.&#xD;
&#xD;
      Safety.&#xD;
&#xD;
      The safety will be assessed at every visit by clinical and laboratory examinations.&#xD;
      Specifically, clinical assessment will include physical examination, vital signs, muscle&#xD;
      function index, manual muscle strength test, MYOACT, MITAX, MYODAM, MDI, HAQ and global&#xD;
      assessment of activity and damage by physician and patient.&#xD;
&#xD;
      Laboratory assessments will include complete blood count, blood chemistry including SGOT&#xD;
      (AST), SGPT (ALT), Na, K, creatinine, LDH, CK, CRP and urine pregnancy test if required by&#xD;
      local practice.&#xD;
&#xD;
      In patients with pulmonary alveolitis or interstitial fibrosis at the start of the study -&#xD;
      HRCT should be performed. If significant progress of pulmonary infiltrate will occur, this is&#xD;
      considered to be treatment failure and patient will be treated according to standard&#xD;
      approach.&#xD;
&#xD;
      Pulmonary toxicity from methotrexate can be suspected in patients with sudden onset of&#xD;
      nonproductive cough with dyspnea. HRCT should be performed. If there are no other obvious&#xD;
      reasons for these symptoms methotrexate should be discontinued.&#xD;
&#xD;
      If nausea after methotrexate occurs, try to divide the dose or give antinauseous drug. If&#xD;
      there are still unacceptable gastrointestinal side effects, parenteral methotrexate&#xD;
      administration can be considered.&#xD;
&#xD;
      Patient selection&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Age between 18 - 80 years.&#xD;
&#xD;
        2. Patients with definite or probable polymyositis or dermatomyositis diagnosed according&#xD;
           to diagnostic criteria (9, 10) (Appendix 1)&#xD;
&#xD;
        3. Physician's own judgment of the disease activity that requires high dose&#xD;
           immunosuppressive treatment (based on clinical assessment of weakness, elevation of&#xD;
           muscle enzymes and, if available, on magnetic resonance imaging findings).&#xD;
&#xD;
        4. Previously untreated patients with the exception of glucocorticoid treatment up to 8&#xD;
           weeks&#xD;
&#xD;
        5. Signed informed consent.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Treatment with any immunosuppressive drug prior the study start.&#xD;
&#xD;
        2. Treatment with glucocorticoids (&gt; 20 mg of Prednisone or equivalent) more than 8 weeks&#xD;
           prior to study start.&#xD;
&#xD;
        3. Drug induced myositis.&#xD;
&#xD;
        4. Polymyositis and dermatomyositis in association with other connective tissue disease.&#xD;
&#xD;
        5. Inclusion body myositis.&#xD;
&#xD;
        6. Patients with immunodeficiency syndrome.&#xD;
&#xD;
        7. Pregnancy and lactation.&#xD;
&#xD;
        8. Fertile women not using adequate contraception during the study, women planning to have&#xD;
           children during the study course or 12 months after the end of the study.&#xD;
&#xD;
        9. Malignancy.&#xD;
&#xD;
       10. Juvenile dermatomyositis.&#xD;
&#xD;
       11. Uncontrolled, clinically significant hematological, cardiovascular, pulmonary,&#xD;
           endocrine, metabolic, gastrointestinal, hepatic or renal disease, which according to&#xD;
           physician's consideration would interfere with high dose glucocorticoid and&#xD;
           immunosuppressive treatment or would prevent to follow the treatment protocol.&#xD;
&#xD;
       12. Severe infection.&#xD;
&#xD;
       13. History of drug or alcohol abuse within the previous 6 months.&#xD;
&#xD;
       14. Patients known to be HIV positive.&#xD;
&#xD;
       15. Known hypersensitivity to methotrexate.&#xD;
&#xD;
      Withdrawal from study.&#xD;
&#xD;
      Patients will be withdrawn from the study due to following reasons:&#xD;
&#xD;
        1. non-compliance with the study protocol&#xD;
&#xD;
        2. positive pregnancy for female patients test during the course of the study&#xD;
&#xD;
        3. if worsening occurs&#xD;
&#xD;
        4. use of prohibited concomitant treatment&#xD;
&#xD;
        5. any adverse event which in the investigatorÂ´s opinion may compromise health of a study&#xD;
           subject&#xD;
&#xD;
      Treatment MTX will be administered orally (in case of oral intolerance intramusculary&#xD;
      (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation&#xD;
      starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours&#xD;
      after each methotrexate dose.&#xD;
&#xD;
      Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered&#xD;
      gradually equally in the two arms&#xD;
&#xD;
      Concomitant medication and treatment:&#xD;
&#xD;
      Recommended medication- Five to ten mg of folic acid will be given 24 hours after each&#xD;
      methotrexate dose.&#xD;
&#xD;
      Prohibited medication: Other immunosuppressive agents are not allowed. All other medication&#xD;
      is allowed at the discretion of the investigator.&#xD;
&#xD;
      Study flowchart Controls and visits will be organized: Day 0 (Baseline), in the 2.week, in&#xD;
      the 1.,2., 3. 4., 5., 6., 7., 8., 9. 10. 11. and 12.month (Termination visit), than one year&#xD;
      Follow-up&#xD;
&#xD;
      Statistics.&#xD;
&#xD;
      Summary statistics of the baseline characteristics will be tabulated by treatment group.&#xD;
&#xD;
      The main population for evaluation will be the ITT (intent- to-treat) population. Summary&#xD;
      statistics (N, mean, standard deviation, median, minimum and maximum) will be presented for&#xD;
      each treatment group by visit for the continuous variables. For the categorical variables N&#xD;
      and % will be presented for each treatment group at endpoint.&#xD;
&#xD;
      A total number of 50 patients with polymyositis/dermatomyositis are planned to be randomized.&#xD;
      These will be equally distributed between the two groups providing 25 patients per treatment&#xD;
      arm. Two-sided tests at the 5% level of significance The primary endpoint that will be&#xD;
      measured is the total dose of glucocorticoids (in mg/kg weight) administered between baseline&#xD;
      and end of treatment.&#xD;
&#xD;
      Between treatment differences will be tested using parametric (t-test) and non-parametric&#xD;
      tests (Mann-Whitney test).&#xD;
&#xD;
      The secondary efficacy variables are disease activity and damage measures, which will be&#xD;
      assessed by myositis disease activity assessment tools (MYOACT and MITAX), myositis damage&#xD;
      tools (MYODAM, MDI), and global assessment of activity and damage by patients and by&#xD;
      physician The continuous secondary variables at endpoint will be tested for treatment&#xD;
      differences using parametric (t-test, ANOVA) and non-parametric tests (Mann-Whitney test,&#xD;
      Kruskal-Wallis ANOVA).&#xD;
&#xD;
      In the event that at the time of statistical analysis any of the model assumptions are not&#xD;
      met data transformations or alternative methods of analysis will be performed as appropriate.&#xD;
&#xD;
      The categorical secondary efficacy variables will be tested for treatment differences using&#xD;
      Fischer's exact test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment.</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint which has benn measured was the total dose of glucocorticoids administered between baseline and the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Disease Activity and Damage,Muscle Strength and Endurance, Enzyme Levels, Glucocorticoid Side-effects, Dose, HAQ,SF-36, Treatment Failures</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Polymyositis</condition>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Prednison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.&#xD;
ARM 1 has only Prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednison + methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms</description>
    <arm_group_label>Prednison</arm_group_label>
    <arm_group_label>Prednison + methotrexate</arm_group_label>
    <other_name>Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.</description>
    <arm_group_label>Prednison + methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 - 80 years.&#xD;
&#xD;
          2. Patients with definite or probable polymyositis or dermatomyositis diagnosed according&#xD;
             to diagnostic criteria (9, 10) (Appendix 1)&#xD;
&#xD;
          3. Physician's own judgment of the disease activity that requires high dose&#xD;
             immunosuppressive treatment (based on clinical assessment of weakness, elevation of&#xD;
             muscle enzymes and, if available, on magnetic resonance imaging findings).&#xD;
&#xD;
          4. Previously untreated patients with the exception of glucocorticoid treatment up to 8&#xD;
             weeks&#xD;
&#xD;
          5. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any immunosuppressive drug prior the study start.&#xD;
&#xD;
          2. Treatment with glucocorticoids (&gt; 20 mg of Prednisone or equivalent) more than 8 weeks&#xD;
             prior to study start.&#xD;
&#xD;
          3. Drug induced myositis.&#xD;
&#xD;
          4. Polymyositis and dermatomyositis in association with other connective tissue disease.&#xD;
&#xD;
          5. Inclusion body myositis.&#xD;
&#xD;
          6. Patients with immunodeficiency syndrome.&#xD;
&#xD;
          7. Pregnancy and lactation.&#xD;
&#xD;
          8. Fertile women not using adequate contraception during the study, women planning to&#xD;
             have children during the study course or 12 months after the end of the study.&#xD;
&#xD;
          9. Malignancy.&#xD;
&#xD;
         10. Juvenile dermatomyositis.&#xD;
&#xD;
         11. Uncontrolled, clinically significant hematological, cardiovascular, pulmonary,&#xD;
             endocrine, metabolic, gastrointestinal, hepatic or renal disease, which according to&#xD;
             physician's consideration would interfere with high dose glucocorticoid and&#xD;
             immunosuppressive treatment or would prevent to follow the treatment protocol.&#xD;
&#xD;
         12. Severe infection.&#xD;
&#xD;
         13. History of drug or alcohol abuse within the previous 6 months.&#xD;
&#xD;
         14. Patients known to be HIV positive.&#xD;
&#xD;
         15. Known hypersensitivity to methotrexate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiri Vencovsky, prof. MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Rheumatology, Prague</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Prague</city>
        <zip>12850</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <results_first_submitted>October 29, 2015</results_first_submitted>
  <results_first_submitted_qc>April 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2016</results_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polymyositis</keyword>
  <keyword>Dermatomyositis</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Polymyositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Trial has reached 62% of planned recruitment (31 patients randomized).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1Prednison</title>
          <description>Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.&#xD;
ARM 1 has only Prednisone&#xD;
Prednisone: Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms</description>
        </group>
        <group group_id="P2">
          <title>2Prednison MTX</title>
          <description>MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.&#xD;
Methotrexate: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1Prednison</title>
          <description>Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.&#xD;
ARM 1 has only Prednisone&#xD;
Prednisone: Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms</description>
        </group>
        <group group_id="B2">
          <title>2Prednison MTX</title>
          <description>MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.&#xD;
Methotrexate: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="14.4"/>
                    <measurement group_id="B2" value="53.5" spread="17.4"/>
                    <measurement group_id="B3" value="52.6" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment.</title>
        <description>The primary endpoint which has benn measured was the total dose of glucocorticoids administered between baseline and the end of treatment.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prednison1</title>
            <description>Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.&#xD;
ARM 1 has only Prednisone&#xD;
Prednisone: Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms</description>
          </group>
          <group group_id="O2">
            <title>Prednison Methotrexate 2</title>
            <description>MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.&#xD;
Methotrexate: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment.</title>
          <description>The primary endpoint which has benn measured was the total dose of glucocorticoids administered between baseline and the end of treatment.</description>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" spread="65.7"/>
                    <measurement group_id="O2" value="135" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Disease Activity and Damage,Muscle Strength and Endurance, Enzyme Levels, Glucocorticoid Side-effects, Dose, HAQ,SF-36, Treatment Failures</title>
        <time_frame>1 year</time_frame>
        <posting_date>12/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Prednison</title>
          <description>Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.&#xD;
ARM 1 has only Prednisone&#xD;
Prednisone: Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms</description>
        </group>
        <group group_id="E2">
          <title>2 Prednison Methotrexate</title>
          <description>MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.&#xD;
Methotrexate: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>synkopa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of muscles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>tumor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>endocrine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>general</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neurological</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychiatric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>gynecological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rheumatology Institute Prague</name_or_title>
      <organization>Rheumatology Institute Prague</organization>
      <phone>+420234075111</phone>
      <email>vencovsky@revma.cz</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

